Cambridge-based synthetic genomics startup Constructive Bio has secured $58m (£43.4m) for the first close of its Series A round.
Founded in 2021, Constructive Bio is developing programmable molecules through its genomics synthesis process.
The firm hopes to engineer molecules with novel properties and functions to support pharmaceutical and therapeutic treatments.
“Constructive Bio is the only company that can turn living cells into sustainable biofactories in which we can programme the sequence, composition and chemistry of proteins, and new biopolymers,” said Constructive Bio founder Prof Jason Chin.
“We have the best technology and an unmatched synergy across our three foundational platforms: deeply recoded synthetic genomes, engineered cellular machinery, and new chemistry.”
The latest funding injection, led by Ahren, OMX Ventures and Paladin Capital Group, brings the total amount raised by the company to $75m.
“It has been amazing to witness the evolution of Constructive Bio’s truly unique bioengineering and biomanufacturing platform technologies,” said Paladin Capital managing director Paul Conley.
“We are honoured to be backing this impressive team as they move swiftly to realise the full potential of the technology with breakthrough medicines, enzymes and biomaterials in the future.”
Additional funding came from Fine Structure Ventures, +ND Capital and Abcam founder Jonathan Milner.
Constructive Bio raised £12.5m in a seed round in August 2022.